Jose Luis Martin-Ventura

List of Publications by Year
in descending order

154 **papers**	6,687 **citations**	53939 47 **h-index**	90395 73 **g-index**
163 **all docs**	163 **docs citations**	163 **times ranked**	9579 **citing authors**

#	ARTICLE	IF	CITATIONS
1	Role of Extracellular Vesicles as Potential Diagnostic and/or Therapeutic Biomarkers in Chronic Cardiovascular Diseases. Frontiers in Cell and Developmental Biology, 2022, 10, 813885.	1.8	19
2	Impacto de la función renal en el valor pronóstico del metabolismo mineral en pacientes con cardiopatía isquémica crónica. Clínica E Investigación En Arteriosclerosis, 2022, 34, 1-9.	0.4	1
3	Impact of renal function on the prognostic value of mineral metabolism in patients with chronic ischaemic heart disease patients with chronic ischaemic heart disease. Clínica E Investigación En Arteriosclerosis (English Edition), 2022, , .	0.1	0
4	Combined Immunoglobulin Free Light Chains Are Novel Predictors of Cardiovascular Events in Patients With Abdominal Aortic Aneurysm. European Journal of Vascular and Endovascular Surgery, 2022, 63, 751-758.	0.8	2
5	Galectin-1 prevents pathological vascular remodeling in atherosclerosis and abdominal aortic aneurysm. Science Advances, 2022, 8, eabm7322.	4.7	18
6	NT-proBNP Levels Influence the Prognostic Value of Mineral Metabolism Biomarkers in Coronary Artery Disease. Journal of Clinical Medicine, 2022, 11, 4153.	1.0	1
7	ALDH4A1 is an atherosclerosis auto-antigen targeted by protective antibodies. Nature, 2021, 589, 287-292.	13.7	72
8	Protective effect of suppressor of cytokine signalling 1â€based therapy in experimental abdominal aortic aneurysm. British Journal of Pharmacology, 2021, 178, 564-581.	2.7	14
9	MCP-1 Predicts Recurrent Cardiovascular Events in Patients with Persistent Inflammation. Journal of Clinical Medicine, 2021, 10, 1137.	1.0	14
10	Extracellular Tuning of Mitochondrial Respiration Leads to Aortic Aneurysm. Circulation, 2021, 143, 2091-2109.	1.6	54
11	Parathormone levels add prognostic ability to Nâ€terminal proâ€brain natriuretic peptide in stable coronary patients. ESC Heart Failure, 2021, 8, 2713-2722.	1.4	10
12	N-Terminal Pro-Brain Natriuretic Peptide Plasma Levels Are Associated with Intermediate-Term Follow-Up Cancer in Coronary Patients. Journal of Clinical Medicine, 2021, 10, 4042.	1.0	2
13	Malondialdehyde-modified HDL particles elicit a specific IgG response in abdominal aortic aneurysm. Free Radical Biology and Medicine, 2021, 174, 171-181.	1.3	3
14	IgG Anti-High Density Lipoprotein Antibodies Are Elevated in Abdominal Aortic Aneurysm and Associated with Lipid Profile and Clinical Features. Journal of Clinical Medicine, 2020, 9, 67.	1.0	12
15	Monocyte Chemoattractant Protein-1 Is an Independent Predictor of Coronary Artery Ectasia in Patients with Acute Coronary Syndrome. Journal of Clinical Medicine, 2020, 9, 3037.	1.0	7
16	CD163 deficiency increases foam cell formation and plaque progression in atherosclerotic mice. FASEB Journal, 2020, 34, 14960-14976.	0.2	13
17	Red Blood Cells and Hemoglobin in Human Atherosclerosis and Related Arterial Diseases. International Journal of Molecular Sciences, 2020, 21, 6756.	1.8	39
18	Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (TWEAK)/Fibroblast Growth Factor-Inducible 14 (Fn14) Axis in Cardiovascular Diseases: Progress and Challenges. Cells, 2020, 9, 405.	1.8	21

#	ARTICLE	IF	CITATIONS
19	Macrophage Cholesterol Efflux Downregulation Is Not Associated with Abdominal Aortic Aneurysm (AAA) Progression. Biomolecules, 2020, 10, 662.	1.8	2
20	Galectin-3 is Associated with Cardiovascular Events in Post-Acute Coronary Syndrome Patients with Type-2 Diabetes. Journal of Clinical Medicine, 2020, 9, 1105.	1.0	15
21	Complement C5 Protein as a Marker of Subclinical Atherosclerosis. Journal of the American College of Cardiology, 2020, 75, 1926-1941.	1.2	32
22	A major role of TWEAK/Fn14 axis as a therapeutic target for post-angioplasty restenosis. EBioMedicine, 2019, 46, 274-289.	2.7	21
23	Role of complement system in pathological remodeling of the vascular wall. Molecular Immunology, 2019, 114, 207-215.	1.0	29
24	Pathophysiology of abdominal aortic aneurysm: biomarkers and novel therapeutic targets. ClÃnica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2019, 31, 166-177.	0.1	3
25	APOA1 oxidation is associated to dysfunctional high-density lipoproteins in human abdominal aortic aneurysm. EBioMedicine, 2019, 43, 43-53.	2.7	40
26	FisiopatologÃa del aneurisma de aorta abdominal: biomarcadores y nuevas dianas terapÃ©uticas. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2019, 31, 166-177.	0.4	20
27	Arachidonic Acid, but Not Omega€3 Index, Relates to the Prevalence and Progression of Abdominal Aortic Aneurysm in a Population€Based Study of Danish Men. Journal of the American Heart Association, 2018, 7, .	1.6	15
28	Combination of biomarkers of vascular calcification and sTWEAK to predict cardiovascular events in chronic kidney disease. Atherosclerosis, 2018, 270, 13-20.	0.4	22
29	Potential role of insulin receptor isoforms and IGF receptors in plaque instability of human and experimental atherosclerosis. Cardiovascular Diabetology, 2018, 17, 31.	2.7	13
30	Impaired HDL (High-Density Lipoprotein)-Mediated Macrophage Cholesterol Efflux in Patients With Abdominal Aortic Aneurysm€"Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 2750-2754.	1.1	13
31	TWEAK blockade decreases atherosclerotic lesion size and progression through suppression of STAT1 signaling in diabetic mice. Scientific Reports, 2017, 7, 46679.	1.6	14
32	Soluble TWEAK and atheromatosis progression in patients with chronic kidney disease. Atherosclerosis, 2017, 260, 130-137.	0.4	18
33	Oxidative Stress in Human Atherothrombosis: Sources, Markers and Therapeutic Targets. International Journal of Molecular Sciences, 2017, 18, 2315.	1.8	45
34	Quantitative HDL Proteomics Identifies Peroxiredoxin-6 as a Biomarker of Human Abdominal Aortic Aneurysm. Scientific Reports, 2016, 6, 38477.	1.6	29
35	A Single In-Vial Dual Extraction Strategy for the Simultaneous Lipidomics and Proteomics Analysis of HDL and LDL Fractions. Journal of Proteome Research, 2016, 15, 1762-1775.	1.8	35
36	Down-regulation of Fibulin-5 is associated with aortic dilation: role of inflammation and epigenetics. Cardiovascular Research, 2016, 110, 431-442.	1.8	36

#	Article	IF	Citations
37	Vascular Proteomics. , 2016, , 105-122.		0
38	Proteomics and metabolomics in biomarker discovery for cardiovascular diseases: progress and potential. Expert Review of Proteomics, 2016, 13, 857-871.	1.3	11
39	ANGPTL4 deficiency in haematopoietic cells promotes monocyte expansion and atherosclerosis progression. Nature Communications, 2016, 7, 12313.	5.8	71
40	Lipocalin-2 deficiency or blockade protects against aortic abdominal aneurysm development in mice. Cardiovascular Research, 2016, 111, 262-273.	1.8	38
41	Soluble TWEAK and Major Adverse Cardiovascular Events in Patients with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 413-422.	2.2	19
42	Plasma Levels of Monocyte Chemoattractant Protein-1, n-Terminal Fragment of Brain Natriuretic Peptide and Calcidiol Are Independently Associated with the Complexity of Coronary Artery Disease. PLoS ONE, 2016, 11, e0152816.	1.1	12
43	Targeted gold-coated iron oxide nanoparticles for CD163 detection in atherosclerosis by MRI. Scientific Reports, 2015, 5, 17135.	1.6	62
44	ApoA-I/HDL-C levels are inversely associated with abdominal aortic aneurysm progression. Thrombosis and Haemostasis, 2015, 113, 1335-1346.	1.8	41
45	The Prognostic Value of High-Sensitive Troponin I in Stable Coronary Artery Disease Depends on Age and Other Clinical Variables. Cardiology, 2015, 132, 1-8.	0.6	15
46	Soluble TWEAK levels predict the presence of carotid atherosclerotic plaques in subjects free from clinical cardiovascular diseases. Atherosclerosis, 2015, 239, 358-363.	0.4	15
47	TWEAK/Fn14 interaction promotes oxidative stress through NADPH oxidase activation in macrophages. Cardiovascular Research, 2015, 108, 139-147.	1.8	40
48	Differential profile in inflammatory and mineral metabolism biomarkers in patients with ischemic heart disease without classical coronary risk factors. Journal of Cardiology, 2015, 66, 22-27.	0.8	15
49	Thioredoxin-1/peroxiredoxin-1 as sensors of oxidative stress mediated by NADPH oxidase activity in atherosclerosis. Free Radical Biology and Medicine, 2015, 86, 352-361.	1.3	34
50	Hemoglobin induces monocyte recruitment and CD163-macrophage polarization in abdominal aortic aneurysm. International Journal of Cardiology, 2015, 201, 66-78.	0.8	22
51	N-Terminal Pro-Brain Natriuretic Peptide Is Associated with a Future Diagnosis of Cancer in Patients with Coronary Artery Disease. PLoS ONE, 2015, 10, e0126741.	1.1	15
52	From tissue iron retention to low systemic haemoglobin levels, new pathophysiological biomarkers of human abdominal aortic aneurysm. Thrombosis and Haemostasis, 2014, 112, 87-95.	1.8	30
53	Genetic deletion or <scp>TWEAK</scp> blocking antibody administration reduce atherosclerosis and enhance plaque stability in mice. Journal of Cellular and Molecular Medicine, 2014, 18, 721-734.	1.6	39
54	Galectinâ€3, a Biomarker Linking Oxidative Stress and Inflammation With the Clinical Outcomes of Patients With Atherothrombosis. Journal of the American Heart Association, 2014, 3, .	1.6	116

#	Article	IF	Citations
55	Tumor Necrosis Factor–Like Weak Inducer of Apoptosis or Fn14 Deficiency Reduce Elastase Perfusion–Induced Aortic Abdominal Aneurysm in Mice. Journal of the American Heart Association, 2014, 3, .	1.6	21
56	Assessment of Biomarkers and Predictive Model for Short-term Prospective Abdominal Aortic Aneurysm Growth—A Pilot Study. Annals of Vascular Surgery, 2014, 28, 1642-1648.	0.4	27
57	RNA binding protein HuR regulates the expression of ABCA1. Journal of Lipid Research, 2014, 55, 1066-1076.	2.0	33
58	Label–free quantitative proteomic analysis of human plasma–derived microvesicles to find protein signatures of abdominal aortic aneurysms. Proteomics - Clinical Applications, 2014, 8, 620-625.	0.8	26
59	Label–free proteomic analysis of red blood cell membrane fractions from abdominal aortic aneurysm patients. Proteomics - Clinical Applications, 2014, 8, 626-630.	0.8	11
60	Usefulness of a Combination of Monocyte Chemoattractant Protein-1, Galectin-3, and N-Terminal Probrain Natriuretic Peptide to Predict Cardiovascular Events in Patients With Coronary Artery Disease. American Journal of Cardiology, 2014, 113, 434-440.	0.7	66
61	Pathology of human plaque vulnerability: Mechanisms and consequences of intraplaque haemorrhages. Atherosclerosis, 2014, 234, 311-319.	0.4	135
62	Identification of Novel Biomarkers of Abdominal Aortic Aneurysms by 2D-DIGE and MALDI-MS from AAA-Thrombus-Conditioned Media. Methods in Molecular Biology, 2013, 1000, 91-101.	0.4	3
63	Unraveling Biomarkers of Abdominal Aortic Aneurisms by iTRAQ Analysis of Depleted Plasma. Methods in Molecular Biology, 2013, 1000, 157-166.	0.4	2
64	Proteomic Analysis of Intraluminal Thrombus Highlights Complement Activation in Human Abdominal Aortic Aneurysms. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 2013-2020.	1.1	50
65	HMGB1 Expression and Secretion Are Increased Via TWEAK–Fn14 Interaction in Atherosclerotic Plaques and Cultured Monocytes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 612-620.	1.1	45
66	Statin Use in Aortic Aneurismal Disease to Prevent Progression and Cardiovascular Events: Review of Experimental and Clinical Data. Current Vascular Pharmacology, 2013, 11, 299-304.	0.8	10
67	Soluble TWEAK is associated with atherosclerotic burden in patients with chronic kidney disease. Journal of Nephrology, 2013, 26, 1105-1113.	0.9	22
68	Oxidative Stress in Cardiovascular Pathologies: Genetics, Cellular, and Molecular Mechanisms and Future Antioxidant Therapies. Oxidative Medicine and Cellular Longevity, 2012, 2012, 1-3.	1.9	8
69	From intraplaque haemorrhages to plaque vulnerability. Journal of Cardiovascular Medicine, 2012, 13, 628-634.	0.6	42
70	HSP90 inhibition by 17-DMAG attenuates oxidative stress in experimental atherosclerosis. Cardiovascular Research, 2012, 95, 116-123.	1.8	67
71	Increased plasma levels of NGAL, a marker of neutrophil activation, in patients with abdominal aortic aneurysm. Atherosclerosis, 2012, 220, 552-556.	0.4	52
72	Cell Stress Proteins in Atherothrombosis. Oxidative Medicine and Cellular Longevity, 2012, 2012, 1-10.	1.9	9

#	ARTICLE	IF	CITATIONS
73	Erythrocytes, leukocytes and platelets as a source of oxidative stress in chronic vascular diseases: Detoxifying mechanisms and potential therapeutic options. Thrombosis and Haemostasis, 2012, 108, 435-442.	1.8	58
74	Metabolomic study of plasma of patients with abdominal aortic aneurysm. Analytical and Bioanalytical Chemistry, 2012, 403, 1651-1660.	1.9	22
75	Metabolomics with LC-QTOF-MS Permits the Prediction of Disease Stage in Aortic Abdominal Aneurysm Based on Plasma Metabolic Fingerprint. PLoS ONE, 2012, 7, e31982.	1.1	61
76	Study of the capillary electrophoresis profile of intact Î±-1-acid glycoprotein isoforms as a biomarker of atherothrombosis. Analyst, The, 2011, 136, 816-822.	1.7	32
77	Metabolites Secreted by Human Atherothrombotic Aneurysms Revealed through a Metabolomic Approach. Journal of Proteome Research, 2011, 10, 1374-1382.	1.8	31
78	Impact of soluble TWEAK and CD163/TWEAK ratio on long-term cardiovascular mortality in patients with peripheral arterial disease. Atherosclerosis, 2011, 219, 892-899.	0.4	50
79	Heat-shock proteins in cardiovascular disease. Advances in Clinical Chemistry, 2011, 54, 1-43.	1.8	32
80	Vascular proteomics and the discovery process of clinical biomarkers: The case of TWEAK. Proteomics - Clinical Applications, 2011, 5, 281-288.	0.8	17
81	Targeted and non-targeted metabolic time trajectory in plasma of patients after acute coronary syndrome. Journal of Pharmaceutical and Biomedical Analysis, 2011, 56, 343-351.	1.4	24
82	TWEAK-Fn14 interaction enhances plasminogen activator inhibitor 1 and tissue factor expression in atherosclerotic plaques and in cultured vascular smooth muscle cells. Cardiovascular Research, 2011, 89, 225-233.	1.8	37
83	Identification of Peroxiredoxin-1 as a Novel Biomarker of Abdominal Aortic Aneurysm. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 935-943.	1.1	75
84	Proteomic Analysis of Polymorphonuclear Neutrophils Identifies Catalase as a Novel Biomarker of Abdominal Aortic Aneurysm: Potential Implication of Oxidative Stress in Abdominal Aortic Aneurysm Progression. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 3011-3019.	1.1	71
85	Diagnostic and therapeutic strategies for small abdominal aortic aneurysms. Nature Reviews Cardiology, 2011, 8, 338-347.	6.1	63
86	CCL20 Is Increased in Hypercholesterolemic Subjects and Is Upregulated By LDL in Vascular Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 2733-2741.	1.1	47
87	Animal Models of Cardiovascular Diseases. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-13.	3.0	287
88	Induction of Macrophage Chemotaxis by Aortic Extracts from Patients with Marfan Syndrome Is Related to Elastin Binding Protein. PLoS ONE, 2011, 6, e20138.	1.1	30
89	Proteomic and Metabolomic Profiles in Atherothrombotic Vascular Disease. Current Atherosclerosis Reports, 2010, 12, 202-208.	2.0	26
90	Local Non-Esterified Fatty Acids Correlate With Inflammation in Atheroma Plaques of Patients With Type 2 Diabetes. Diabetes, 2010, 59, 1292-1301.	0.3	49

#	ARTICLE	IF	CITATIONS
91	Peripheral Artery Disease Is Associated With a High CD163/TWEAK Plasma Ratio. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1253-1262.	1.1	67
92	Combined Therapy with Renin-Angiotensin System and Calcium Channel Blockers in Type 2 Diabetic Hypertensive Patients with Proteinuria. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1174-1181.	2.2	63
93	Heat shock protein 90 inhibitors attenuate inflammatory responses in atherosclerosis. Cardiovascular Research, 2010, 86, 330-337.	1.8	116
94	Proteomic Strategies in the Search of New Biomarkers in Atherothrombosis. Journal of the American College of Cardiology, 2010, 55, 2009-2016.	1.2	41
95	The MIF Receptor CD74 in Diabetic Podocyte Injury. Journal of the American Society of Nephrology: JASN, 2009, 20, 353-362.	3.0	94
96	Leukotriene B4 enhances the activity of nuclear factor-ÂB pathway through BLT1 and BLT2 receptors in atherosclerosis. Cardiovascular Research, 2009, 81, 216-225.	1.8	114
97	Additive Effects of Soluble TWEAK and Inflammation on Mortality in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 110-118.	2.2	106
98	Increased CD74 expression in human atherosclerotic plaques: contribution to inflammatory responses in vascular cells. Cardiovascular Research, 2009, 83, 586-594.	1.8	55
99	The Proteomic Approach in the Development of Prognostic Biomarkers in Atherothrombosis. Recent Patents on Cardiovascular Drug Discovery, 2009, 4, 25-30.	1.5	5
100	Soluble TWEAK Plasma Levels as a Novel Biomarker of Endothelial Function in Patients with Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1716-1723.	2.2	78
101	Tumor Necrosis Factorâ€"Like Weak Inducer of Apoptosis (TWEAK) Enhances Vascular and Renal Damage Induced by Hyperlipidemic Diet in ApoE-Knockout Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 2061-2068.	1.1	101
102	Suppressors of Cytokine Signaling Modulate JAK/STAT-Mediated Cell Responses During Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 525-531.	1.1	110
103	Considering TWEAK as a target for therapy in renal and vascular injury. Cytokine and Growth Factor Reviews, 2009, 20, 251-258.	3.2	57
104	Cardiovascular Risk and Antiangiogenic Therapy for Age-related Macular Degeneration. Survey of Ophthalmology, 2009, 54, 339-348.	1.7	47
105	Improving Metabolite Knowledge in Stable Atherosclerosis Patients by Association and Correlation of GC-MS and ^{1}H NMR Fingerprints. Journal of Proteome Research, 2009, 8, 5580-5589.	1.8	70
106	Biomarkers in Cardiovascular Medicine. Revista Espanola De Cardiologia (English Ed), 2009, 62, 677-688.	0.4	28
107	Vascular proteomics, a translational approach: from traditional to novel proteomic techniques. Expert Review of Proteomics, 2009, 6, 461-464.	1.3	8
108	The CD163-expressing macrophages recognize and internalize TWEAK. Atherosclerosis, 2009, 207, 103-110.	0.4	129

#	Article	IF	Citations
109	Biomarcadores en la medicina cardiovascular. Revista Espanola De Cardiologia, 2009, 62, 677-688.	0.6	47
110	Respuesta. Revista Espanola De Cardiologia, 2009, 62, 1342-1343.	0.6	0
111	Proteomics in atherosclerosis. Current Atherosclerosis Reports, 2008, 10, 209-215.	2.0	12
112	Effect of Intensive Atorvastatin Therapy on Prostaglandin E2 Levels and Metalloproteinase-9 Activity in the Plasma of Patients With Non-ST-Elevation Acute Coronary Syndromeâ€â€Conflicts of interest: Drs. Egido and TuÃ±Ã³n have participated on advisory boards and have been invited speakers for Pfizer.. American Journal of Cardiology, 2008, 102, 12-18.	0.7	42
113	Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk. European Journal of Pharmacology, 2008, 586, 259-265.	1.7	35
114	Soluble Fas ligand plasma levels are associated with forearm reactive hyperemia in subjects with coronary artery disease. Atherosclerosis, 2008, 201, 407-412.	0.4	20
115	LDL induces parathyroid hormone-related protein expression in vascular smooth muscle cells: Modulation by simvastatin. Atherosclerosis, 2008, 198, 264-271.	0.4	7
116	Plasma Concentration of Heat Shock Protein 27 and Risk of Cardiovascular Disease: A Prospective, Nested Case-Control Study. Clinical Chemistry, 2008, 54, 139-146.	1.5	38
117	Atorvastatin decreases elevated soluble CD40L in subjects at high cardiovascular risk. Atorvastatin on inflammatory markers study: a substudy of ACTFAST. Kidney International, 2008, 74, S60-S63.	2.6	17
118	Treatment with amlodipine and atorvastatin has additive effect on blood and plaque inflammation in hypertensive patients with carotid atherosclerosis. Kidney International, 2008, 74, S71-S74.	2.6	20
119	Proteomic Analysis of Circulating Monocytes Identifies Cathepsin D as A Potential Novel Plasma Marker of Acute Coronary Syndromes. Clinical Medicine Cardiology, 2008, 2, CMC.S654.	0.1	3
120	Characterization of HSP27 Phosphorylation Sites in Human Atherosclerotic Plaque Secretome. , 2007, 357, 151-164.		9
121	Characterization of the Human Atheroma Plaque Secretome by Proteomic Analysis. , 2007, 357, 141-150.		21
122	Mechanisms of action of statins in stroke. Expert Opinion on Therapeutic Targets, 2007, 11, 273-278.	1.5	14
123	Increased Soluble Fas Plasma Levels in Subjects at High Cardiovascular Risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 168-174.	1.1	53
124	Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: A substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration. American Heart Journal, 2007, 153, 881-888.	1.2	76
125	Ethanol beverages containing polyphenols decrease nuclear factor kappa-B activation in mononuclear cells and circulating MCP-1 concentrations in healthy volunteers during a fat-enriched diet. Atherosclerosis, 2007, 192, 335-341.	0.4	28
126	Low plasma levels of HSP70 in patients with carotid atherosclerosis are associated with increased levels of proteolytic markers of neutrophil activation. Atherosclerosis, 2007, 194, 334-341.	0.4	54

#	Article	IF	Citations
127	Identification of Soluble Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (sTWEAK) as a Possible Biomarker of Subclinical Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 916-922.	1.1	127
128	Proteomics in atherothrombosis: a future perspective. Expert Review of Proteomics, 2007, 4, 249-260.	1.3	13
129	TWEAK and Fn14. New players in the pathogenesis of atherosclerosis. Frontiers in Bioscience - Landmark, 2007, 12, 3648.	3.0	48
130	Trail and vascular injury. Frontiers in Bioscience - Landmark, 2007, 12, 3656.	3.0	14
131	Atorvastatin modulates the profile of proteins released by human atherosclerotic plaques. European Journal of Pharmacology, 2007, 562, 119-129.	1.7	48
132	Common pathways of hypercholesterolemia and hypertension leading to atherothrombosis: the need for a global approach in the management of cardiovascular risk factors. Vascular Health and Risk Management, 2007, 3, 521-6.	1.0	15
133	Overexpression of COX-2, Prostaglandin E Synthase-1 and Prostaglandin E Receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: Regulation by nuclear factor-κB. Atherosclerosis, 2006, 187, 139-149.	0.4	84
134	Atorvastatin Reduces the Expression of Prostaglandin E2 Receptors in Human Carotid Atherosclerotic Plaques and Monocytic Cells. Journal of Cardiovascular Pharmacology, 2006, 47, 60-69.	0.8	70
135	Fn14 Is Upregulated in Cytokine-Stimulated Vascular Smooth Muscle Cells and Is Expressed in Human Carotid Atherosclerotic Plaques. Stroke, 2006, 37, 2044-2053.	1.0	95
136	Biological Significance of Decreased HSP27 in Human Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 1337-1343.	1.1	89
137	Biology of atherosclerotic plaques: What we are learning from proteomic analysis. Cardiovascular Research, 2006, 72, 18-29.	1.8	42
138	Vascular Protection of Dual Therapy (Atorvastatin-Amlodipine) in Hypertensive Patients. Journal of the American Society of Nephrology: JASN, 2006, 17, S189-S193.	3.0	11
139	Proteomic approach in the search of new cardiovascular biomarkers. Kidney International, 2005, 68, S103-S107.	2.6	16
140	Intensive Treatment With Atorvastatin Reduces Inflammation in Mononuclear Cells and Human Atherosclerotic Lesions in One Month. Stroke, 2005, 36, 1796-1800.	1.0	113
141	HMG-CoA Reductase Inhibitors Reduce IκB Kinase Activity Induced by Oxidative Stress in Monocytes and Vascular Smooth Muscle Cells. Journal of Cardiovascular Pharmacology, 2005, 45, 468-475.	0.8	30
142	Quest for Novel Cardiovascular Biomarkers by Proteomic Analysis€. Journal of Proteome Research, 2005, 4, 1181-1191.	1.8	80
143	Inflammatory biomarkers and statins. Drugs of Today, 2005, 41, 171.	2.4	3
144	NF-κB Activation and Fas Ligand Overexpression in Blood and Plaques of Patients With Carotid Atherosclerosis. Stroke, 2004, 35, 458-463.	1.0	91

#	ARTICLE	IF	CITATIONS
145	Intensive treatment with statins and the progression of cardiovascular diseases: the beginning of a new era?. Nephrology Dialysis Transplantation, 2004, 19, 2696-2699.	0.4	4
146	Identification by a Differential Proteomic Approach of Heat Shock Protein 27 as a Potential Marker of Atherosclerosis. Circulation, 2004, 110, 2216-2219.	1.6	214
147	Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis. Journal of the American College of Cardiology, 2004, 43, 1188-1194.	1.2	42
148	Statins in Hypertensive Patients. Drugs, 2004, 64, 61-67.	4.9	5
149	Anti-inflammatory and immunomodulatory effects of statins. Kidney International, 2003, 63, 12-23.	2.6	279
150	Proteomic analysis of human vessels: Application to atherosclerotic plaques. Proteomics, 2003, 3, 973-978.	1.3	107
151	3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Decrease Fas Ligand Expression and Cytotoxicity in Activated Human T Lymphocytes. Circulation, 2003, 108, 1506-1513.	1.6	64
152	Simvastatin reduces NF-κB activity in peripheral mononuclear and in plaque cells of rabbit atheroma more markedly than lipid lowering diet. Cardiovascular Research, 2003, 57, 168-177.	1.8	70
153	Possible Role of Parathyroid Hormone–Related Protein as a Proinflammatory Cytokine in Atherosclerosis. Stroke, 2003, 34, 1783-1789.	1.0	67
154	Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis, 2002, 160, 49-58.	0.4	116